Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes - PubMed (original) (raw)
Characterization of 1'-hydroxymidazolam glucuronidation in human liver microsomes
Bing Zhu et al. Drug Metab Dispos. 2008 Feb.
Abstract
Midazolam is a potent benzodiazepine derivative with sedative, hypnotic, anticonvulsant, muscle-relaxant, and anxiolytic activities. It undergoes oxidative metabolism catalyzed almost exclusively by the CYP3A subfamily to a major metabolite, 1'-hydroxymidazolam, which is equipotent to midazolam. 1'-Hydroxymidazolam is subject to glucuronidation followed by renal excretion. To date, the glucuronidation of 1'-hydroxymidazolam has not been evaluated in detail. In the current study, we identified an unreported quaternary N-glucuronide, as well as the known O-glucuronide, from incubations of 1'-hydroxymidazolam in human liver microsomes enriched with uridine 5'-diphosphoglucuronic acid (UDPGA). The structure of the N-glucuronide was confirmed by nuclear magnetic resonance analysis, which showed that glucuronidation had occurred at N-2 (the imidazole nitrogen that is not a part of the benzodiazepine ring). In a separate study, in which midazolam was used as the substrate, an analogous N-glucuronide also was detected from incubations with human liver microsomes in the presence of UDPGA. Investigation of the kinetics of 1'-hydroxymidazolam glucuronidation in human liver microsomes indicated autoactivation kinetics (Hill coefficient, n = 1.2-1.5). The apparent S(50) values for the formation of O- and N-glucuronides were 43 and 18 microM, respectively, and the corresponding apparent V(max) values were 363 and 21 pmol/mg of microsomal protein/min. Incubations with recombinant human uridine diphosphate glucuronosyltransferases (UGTs) indicated that the O-glucuronidation was catalyzed by UGT2B4 and UGT2B7, whereas the N-glucuronidation was catalyzed by UGT1A4. Consistent with these observations, hecogenin, a selective inhibitor of UGT1A4, selectively inhibited the N-glucuronidation, whereas diclofenac, a potent inhibitor of UGT2B7, had a greater inhibitory effect on the O-glucuronidation than on the N-glucuronidation. In summary, our study provides the first demonstration of N-glucuronidation of 1'-hydroxymidazolam in human liver microsomes.
Similar articles
- Metabolism of 1'- and 4-hydroxymidazolam by glucuronide conjugation is largely mediated by UDP-glucuronosyltransferases 1A4, 2B4, and 2B7.
Seo KA, Bae SK, Choi YK, Choi CS, Liu KH, Shin JG. Seo KA, et al. Drug Metab Dispos. 2010 Nov;38(11):2007-13. doi: 10.1124/dmd.110.035295. Epub 2010 Aug 16. Drug Metab Dispos. 2010. PMID: 20713656 - Regioselective glucuronidation of denopamine: marked species differences and identification of human udp-glucuronosyltransferase isoform.
Kaji H, Kume T. Kaji H, et al. Drug Metab Dispos. 2005 Mar;33(3):403-12. doi: 10.1124/dmd.104.002667. Epub 2004 Dec 17. Drug Metab Dispos. 2005. PMID: 15608137 - Trans-3'-hydroxycotinine O- and N-glucuronidations in human liver microsomes.
Yamanaka H, Nakajima M, Katoh M, Kanoh A, Tamura O, Ishibashi H, Yokoi T. Yamanaka H, et al. Drug Metab Dispos. 2005 Jan;33(1):23-30. doi: 10.1124/dmd.104.001701. Epub 2004 Oct 6. Drug Metab Dispos. 2005. PMID: 15470160 - Saccharolactone: The History, the Myth, and the Practice.
Argikar UA. Argikar UA. Curr Drug Metab. 2018;19(4):304-309. doi: 10.2174/1389200219666171229232007. Curr Drug Metab. 2018. PMID: 29298647 Review. - Complexities of glucuronidation affecting in vitro in vivo extrapolation.
Lin JH, Wong BK. Lin JH, et al. Curr Drug Metab. 2002 Dec;3(6):623-46. doi: 10.2174/1389200023336992. Curr Drug Metab. 2002. PMID: 12369890 Review.
Cited by
- Evidence of CYP3A allosterism in vivo: analysis of interaction between fluconazole and midazolam.
Yang J, Atkins WM, Isoherranen N, Paine MF, Thummel KE. Yang J, et al. Clin Pharmacol Ther. 2012 Mar;91(3):442-9. doi: 10.1038/clpt.2011.178. Epub 2011 Nov 2. Clin Pharmacol Ther. 2012. PMID: 22048224 Free PMC article. - Nutritional Status Differentially Alters Cytochrome P450 3A4 (CYP3A4) and Uridine 5'-Diphospho-Glucuronosyltransferase (UGT) Mediated Drug Metabolism: Effect of Short-Term Fasting and High Fat Diet on Midazolam Metabolism.
Lammers LA, Achterbergh R, Romijn JA, Mathôt RAA. Lammers LA, et al. Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):751-767. doi: 10.1007/s13318-018-0487-5. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29876844 Free PMC article. Clinical Trial. - Prediction of Metabolite-to-Parent Drug Exposure: Derivation and Application of a Mechanistic Static Model.
Callegari E, Varma MVS, Obach RS. Callegari E, et al. Clin Transl Sci. 2020 May;13(3):520-528. doi: 10.1111/cts.12734. Epub 2020 Feb 4. Clin Transl Sci. 2020. PMID: 31880865 Free PMC article. - Population pharmacokinetics of midazolam and its metabolites during venoarterial extracorporeal membrane oxygenation in neonates.
Ahsman MJ, Hanekamp M, Wildschut ED, Tibboel D, Mathot RA. Ahsman MJ, et al. Clin Pharmacokinet. 2010 Jun;49(6):407-19. doi: 10.2165/11319970-000000000-00000. Clin Pharmacokinet. 2010. PMID: 20481651 - Indinavir Increases Midazolam _N_-Glucuronidation in Humans: Identification of an Alternate CYP3A Inhibitor Using an In Vitro to In Vivo Approach.
Tian DD, Leonowens C, Cox EJ, González-Pérez V, Frederick KS, Scarlett YV, Fisher MB, Paine MF. Tian DD, et al. Drug Metab Dispos. 2019 Jul;47(7):724-731. doi: 10.1124/dmd.119.087007. Epub 2019 Apr 26. Drug Metab Dispos. 2019. PMID: 31028057 Free PMC article. Clinical Trial.